Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Invesco

INVESCO Health Care Fund Class R (GTHRX)

Ticker GTHRX · Since 2025-09-30 · · Holdings as of Jul 31, 2026

Expense ratio
1.32%$132/yr per $10k
5-yr return
+3.5%annualized
1-yr return
+15.2%as of Dec 2025
Net assets
$1.2Ball share classes
Holdings
82

Bottom line

Is GTHRX a good fund? The bottom line

GTHRX is the Class R share class of INVESCO Health Care Fund, an actively managed health care sector mutual fund from Invesco.

Annual fees run 1.32% — about $132 a year on every $10,000 invested, more expensive than 74% of health care sector funds we track.

It returned +15.2% over one year, +3.5% a year over five years, +6.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.2 billion in net assets and 82 holdings, its largest position is Eli Lilly and Co. (10.6%) and the top 10 make up 48.5% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 55% top-holdings overlap).

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.32%)
  • 12b-1 marketing fee of 0.5% a year

Updated Nov 19, 2026

What GTHRX invests in

The Funds investment objective is long-term growth of capital.

The Fund invests, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. The Fund will concentrate its investments in the securities of domestic and foreign issuers in the health care industry. The Fund uses various criteria to determine whether an issuer is engaged in health care-related industries, including whether (1) it derives 50% or more of its gross income or its net sales from activities in the health care industry; (2) it devotes 50% or more of its assets to producing revenues from the health care industry; or (3) based on other available information, the Funds portfolio managers determine that its primary business is within the health care…

From the fund's prospectus (filed Feb 27, 2026).

GTHRX performance

Fund calendar-year total returns, 2015–2024 2015: +3.0%; 2016: −11.7%; 2017: +15.5%; 2018: +0.5%; 2019: +32.0%; 2020: +14.5%; 2021: +12.2%; 2022: −13.5%; 2023: +3.1%; 2024: +4.0% +3% 2015 −12% 2016 +15% 2017 +0% 2018 +32% 2019 +14% 2020 +12% 2021 −14% 2022 +3% 2023 +4% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
GTHRX+15.2%+3.5%+6.1%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full GTHRX performance history →

What GTHRX costs

On a $10,000 investment, GTHRX's 1.32% expense ratio costs about $132 a year. The prospectus estimates $1,590 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full GTHRX fee table →

GTHRX top 10 holdings

#Holding% of fund
1Eli Lilly and Co.10.59%
2Johnson & Johnson6.76%
3UnitedHealth Group Inc.6.17%
4Invesco Private Prime Fund4.67%
5Merck & Co., Inc.4.59%
6AbbVie Inc.4.03%
7Gilead Sciences, Inc.3.63%
8argenx SE3.24%
9CVS Health Corp.2.52%
10Welltower Inc.2.34%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 48.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to GTHRX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%55% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%54% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%54% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%52% Compare
SchwabSWHFX Schwab Health Care Fund0.8%51% Compare
T. Rowe PricePRHSX T. Rowe Price Health Sciences Fund, Inc.0.83%59% Compare

More funds like GTHRX →

GTHRX FAQ

What is the expense ratio of GTHRX?
GTHRX's expense ratio is 1.32%, which works out to about $132 a year for every $10,000 invested. The prospectus estimates total costs of $1,590 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is GTHRX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.32%); 12b-1 marketing fee of 0.5% a year. This is general information, not personalized advice.
What does GTHRX hold?
GTHRX's largest holdings are Eli Lilly and Co. (10.6%), Johnson & Johnson (6.8%), UnitedHealth Group Inc. (6.2%), Invesco Private Prime Fund (4.7%), Merck & Co., Inc. (4.6%). It holds 82 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is GTHRX's 5-year return?
GTHRX returned +3.5% a year over the five years ending Dec 31, 2025, and +6.1% a year over ten years. Past performance does not guarantee future results.
Does GTHRX have a sales load?
No. GTHRX has no front-end sales charge.
What is a cheaper alternative to GTHRX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 55% with GTHRX and charges 0.08%.
Who manages GTHRX?
GTHRX is offered by Invesco through Aim Investment Funds (invesco Investment Funds).